Myrbetriq 25 mg is appropriate for a patient with creatinine clearance of 37 mL/min
For a patient with a creatinine clearance of 37 mL/min, Myrbetriq 25 mg once daily is the correct dose and requires no adjustment, as this falls within the moderate renal impairment range (eGFR 30-89 mL/min/1.73 m²) where no dose modification is necessary.
Dosing Based on Renal Function
According to the FDA-approved prescribing information, no dose adjustment is necessary in patients with mild or moderate renal impairment (eGFR 30 to 89 mL/min/1.73 m²) 1. Your patient's creatinine clearance of 37 mL/min places them squarely in the moderate renal impairment category, making the 25 mg dose fully appropriate.
The 25 mg dose limitation only applies to patients with severe renal impairment (eGFR 15 to 29 mL/min/1.73 m²), where the daily dose should not exceed 25 mg 1. Since your patient has a CrCl of 37 mL/min, they are above this threshold and could theoretically be titrated to 50 mg if clinically indicated for symptom control.
Pharmacokinetic Rationale
Research demonstrates that mirabegron exposure increases progressively with declining renal function. In patients with moderate renal impairment (similar to your patient), mirabegron AUC increased by 66% and Cmax by 23% compared to those with normal renal function 2. However, these increases were deemed not clinically significant and did not warrant dose adjustment in this population.
The drug exhibits high pharmacokinetic variability with significant overlap in exposures between patients with renal impairment and healthy subjects 2. Renal clearance of mirabegron averages approximately 13 L/h and accounts for only 7-18% of total elimination, with the majority metabolized hepatically via CYP3A4 3, 4.
Safety Considerations
Mirabegron has been well-tolerated in clinical trials across various renal function levels. The most common adverse effects include hypertension, nasopharyngitis, urinary tract infection, and headache 5, 6. Monitor blood pressure as mirabegron can cause modest increases in systolic and diastolic blood pressure, particularly relevant in patients with any degree of renal impairment.
Contraindications
Myrbetriq is not recommended in patients with end-stage renal disease (eGFR <15 mL/min/1.73 m²) or those requiring hemodialysis, as it has not been studied in these populations 1.
Clinical Bottom Line
Your patient with CrCl 37 mL/min can safely receive Myrbetriq 25 mg once daily without dose adjustment. If inadequate symptom control occurs after 4-8 weeks, titration to 50 mg once daily is permissible and does not require dose reduction based solely on their current level of renal function. Ensure regular monitoring of blood pressure and renal function during treatment.